J&J neurology news

Johnson & Johnson disclosed in its 2Q11 earnings that an agreement in principal has been reached on key issues relevant to a misdemeanor criminal charge related to the promotion of antipsychotic Risperdal risperidone, but certain issues remain open before a settlement can be finalized. The U.S. Department of Justice and the U.S. Attorney's Office for the Eastern District of Pennsylvania are pursing criminal and civil actions concerning sales and marketing of Risperdal, including for off-label uses. The company could not be reached for comment. ...